Where is EditCo located?

EditCo is headquartered in Redwood City, United States.

Is EditCo a funded company?

EditCo is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does EditCo rank among its competitors?

EditCo ranks 154th amongst 927 active competitors, of which 74 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was OXGENE, which secured $1.02M in Jul, 2025.

Who are the top competitors of EditCo?

EditCo's top competitors include Abcam, Meridian Bioscience and Sino Biological. Among them, OXGENE secured the most recent funding round in July, 2025.

EditCo - 2026 Company Profile, Team & Competitors

Company Details

Developer of CRISPR libraries and gene knockout kits. It provides CRISPR guide RNA designs and edited cells for the global cell biology and gene therapy research markets.

Website: www.editco.bio/
Social
Email ID: *****@editco.bio

Key Metrics

Founded Year

2024

Location

Redwood City, United States

Stage

Unfunded

Ranked

154^th among 927 active competitors

Similar Companies

Sino Biological & 446 more

View EditCo's full profile

EditCo has not raised any funding rounds yet.

The founders of EditCo are John Tan and Travis Maures.

Here are the details of EditCo's key team members:

John Tan: Co-Founder & Chief Executive Officer of EditCo.
Travis Maures: Co-Founder & CSO of EditCo.
Contact Info: 1 email address

View details of EditCo's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EditCo include Abcam, Meridian Bioscience and Sino Biological. Here is the list of Top 10 competitors of EditCo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcam 1998, Cambridge (United Kingdom), Acquired	Developer of biological reagents for life science research	$78.8M	Juno Investment Partners, Martlet Capital ... & 2 others	77/100
2nd	Meridian Bioscience 1976, Ohio (United States), Acquired	Molecular diagnostic device and kits	-	NIH, JobsOhio	65/100
3rd	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	CTS Capital, Qiming Venture Partners & 1 others	64/100
4th	ACD 2006, Newark (United States), Acquired	Developer of a transnational research platform for biomarker analysis	$39.4M	Summit Partners, Morningside & 5 others	63/100
5th	Miltenyi Biotec 1989, Bergisch Gladbach (Germany), Funding Raised	Develops tools and products for research and clinical application	-	Europa, HHS	62/100
6th	Enzo 1976, Farmingdale (United States), Acquired	Life science products and services for research, drug discovery, and manufacturing	$7M	-	59/100
7th	Inscripta 2015, Denver (United States), Series E	Developer of gene editing technology for research	$502M	Paladin Capital, Venrock & 19 others	59/100
8th	OXGENE 2011, Oxford (United Kingdom), Acquired	Provider of a platform for mammalian cell engineering	$28.1M	Mercia, Invesco & 6 others	59/100
9th	GenScript 2002, Piscataway (United States), Public	Provider of reagents and instruments for life sciences research	$15M	Kleiner Perkins, Vermögensclub & 1 others	59/100
10th	Promega 1978, Madison (United States), Funding Raised	Provider of genomics, protein analysis and expression, drug discovery, and genetic identification products	-	Venture Investors, NASA & 2 others	59/100
154th	EditCo 2024, Redwood City (United States), Unfunded	Developer of CRISPR libraries and gene knockout kits	-	-	34/100